SS-31 (Elamipretide) Research Guide: Mitochondria-Targeting Peptide and Cardioprotective Mechanisms

By Sam Smith

SS-31 (Elamipretide) works on a target almost no other peptide touches: the inner mitochondrial membrane itself. It binds cardiolipin — a phospholipid that exists almost exclusively at that location — and prevents its oxidation, which is the upstream trigger for cristae collapse and electron transport chain disassembly. Why does cristae architecture matter? Because that’s where ATP synthase lives. Flatten the cristae and you’ve functionally wrecked the cell’s energy production. SS-31 has cleared Phase 2 in heart failure with preserved ejection fraction (HFpEF), making it one of a very small number of mitochondria-targeting compounds with genuine human clinical data. Szeto et al. (2014, JASN) showed that a single IV infusion normalized mitochondrial respiration in ischaemia-reperfusion kidney injury within 24 hours.

Is elamipretide the same as SS-31?

Yes — same molecule, different names. SS-31 is the laboratory name (Szeto-Schiller peptide #31), Elamipretide is the pharmaceutical development name used in clinical trials, and the chemical name is D-Arg-Dmt-Lys-Phe-NH₂. Some literature uses MTP-131 or Bendavia as earlier development names. If you’re reading clinical trial data from the heart failure studies or the kidney injury literature, you’ll see Elamipretide; if you’re reading basic mitochondria research, you’ll see SS-31. Same compound throughout.

The naming confusion trips up literature searches, so it’s worth being explicit: a PubMed search for “SS-31” will miss papers using “Elamipretide” and vice versa. Running both searches is necessary for a complete literature review on this compound.

What SS-31 actually does in mitochondria

The mechanism starts with cardiolipin. Cardiolipin is a phospholipid almost exclusively found in the inner mitochondrial membrane — it’s what anchors cytochrome c and stabilises the protein complexes that form the electron transport chain supercomplexes. When cardiolipin gets oxidised (which happens under oxidative stress and during ageing), it loses its ability to anchor these complexes, the cristae architecture flattens, and ETC efficiency drops. ATP synthesis becomes less efficient. The mitochondrion starts leaking electrons rather than using them productively.

SS-31 selectively concentrates in the inner mitochondrial membrane (roughly 1,000-fold accumulation relative to cytosol) and binds directly to cardiolipin, preventing its peroxidation. Szeto et al. (2014, JASN) demonstrated this produced measurable functional recovery: a single IV infusion in mice with established ischaemia-reperfusion kidney injury normalised mitochondrial respiration rates within 24 hours and cut serum creatinine by 60% at 48 hours. Those effects couldn’t be explained by anti-inflammatory mechanisms — they were too fast and too specifically tied to mitochondrial function markers.

Conditions where SS-31 shows preclinical signals

The mitochondrial dysfunction mechanism explains the range of conditions showing preclinical SS-31 signal. Any disease state where mitochondrial ETC failure, cardiolipin oxidation, or ATP production impairment is pathologically central is a candidate. That list is longer than you might expect: heart failure with preserved ejection fraction (HFpEF, where Phase 2 human data now exists), ischaemia-reperfusion injury (kidney, heart, skeletal muscle), age-related sarcopenia, Alzheimer’s disease models, mitochondrial myopathies, and chemotherapy-induced cardiac toxicity.

Across these conditions, the pattern holds: SS-31 works best when the primary problem is the structural stuff — cardiolipin oxidation, cristae collapse — rather than upstream signalling failure or transcriptional problems. That makes sense mechanistically — it’s binding a structural membrane component, not a receptor or enzyme, so it can’t fix what it can’t reach. The persistence of effects after treatment ends in some models probably reflects this: once cardiolipin architecture is restored, the mitochondrion can maintain its own structure rather than requiring continuous pharmacological support.

Human trial data: what Elamipretide has shown in clinical settings

Two human populations now have Phase 2 data. In HFpEF (heart failure with preserved ejection fraction), the PROGRESS-HF trial showed 4 weeks of subcutaneous Elamipretide significantly improved 6-minute walk test distance versus placebo — a functional endpoint that reflects real-world exercise tolerance. In Barth syndrome (a rare genetic mitochondrial disease), a Phase 2/3 trial showed improvements in muscle strength and walking test performance. Neither led to Phase 3 approval yet. But both are human proof-of-concept — actual disease settings, not animal models — which puts SS-31 in a very different category from most mitochondria-targeting compounds that never left rodent studies.

Safety profile and side effects of SS-31 in research

SS-31’s preclinical toxicology is cleaner than you might expect for a mitochondria-targeting compound. Rodent studies at typical research doses haven’t turned up hepatotoxicity, cardiotoxicity, or renal toxicity. The compound is water-soluble and doesn’t accumulate in fatty tissues, which simplifies its pharmacokinetic profile compared to lipophilic compounds. In PROGRESS-HF, the most common complaint was subcutaneous injection-site reactions — tolerable in a trial context. No serious adverse events were attributed to the compound in that study. Human data is still limited to specific patient populations, so extrapolating safety broadly remains premature.

How does SS-31 elamipretide compare to other peptides?

Within the mitochondria-targeted intervention category, elamipretide has the most developed clinical pipeline. MitoQ (mitoquinone) is the leading small-molecule alternative but is a chain-breaking antioxidant that can become pro-oxidant at high doses. SkQ1 and similar triphenylphosphonium-conjugated antioxidants share the MitoQ class. Among peptide-based mitochondrial interventions, elamipretide is essentially unique in clinical development; humanin, MOTS-c, and SHLPs are still in earlier-phase research without late-phase clinical programs.

Legal status and sourcing

Elamipretide is not yet approved by Health Canada or the FDA as a finished pharmaceutical (Barth syndrome NDA pending). Research-grade SS-31 elamipretide is legal in Canada and the United States as a research chemical sold under research-use-only labelling, distinct from any future finished pharmaceutical. The peptide is not on the World Anti-Doping Agency prohibited list as of 2026.

Reproducible mitochondrial peptide research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~640 Da tetrapeptide molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies SS-31 (elamipretide) with third-party COA and HPLC purity confirmation. View the SS-31 10mg product page.

Clinical trials: ongoing and completed

The elamipretide clinical program is the largest peptide-therapeutic mitochondrial program in current development. Completed Phase 2-3 trials include TAZPOWER (Barth syndrome cardiomyopathy, primary endpoint achieved), SPIBA-201 (Barth syndrome with open-label extension), MMPOWER and MMPOWER-2 (primary mitochondrial myopathy, mixed efficacy results), ReCLAIM and ReCLAIM-2 (dry age-related macular degeneration with improved retinal pigment epithelium function), and PROGRESS-HF (heart failure with preserved ejection fraction, ongoing). The diabetic nephropathy and acute kidney injury programs remain in earlier phases. The cumulative human safety database of elamipretide exposure exceeds 1,500 subjects across all studies, supporting the favourable safety profile reported in published trial data.

SS-31 elamipretide questions

Is elamipretide the same as SS-31?

Yes. SS-31 is the research-development name; elamipretide is the clinical INN. Both refer to the same D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2 tetrapeptide. The peptide has also been called MTP-131 and bendavia.

What does SS-31 elamipretide do?

Enters cells, accumulates in the inner mitochondrial membrane, binds cardiolipin to stabilise cristae architecture, and preserves mitochondrial function under oxidative stress. The mechanism is structural rather than chemical.

What are the benefits of elamipretide peptide?

Preserves mitochondrial membrane potential, reduces mitochondrial ROS, restores mitochondrial ATP production under stress, and reverses cardiolipin peroxidation in ischemia-reperfusion injury. Clinical effects documented in heart failure, Barth syndrome, and macular degeneration.

Is SS-31 elamipretide FDA approved?

Not yet. Stealth BioTherapeutics submitted an NDA in 2024 for Barth syndrome with FDA Priority Review designation. Approval decision expected 2026. Other indications (mitochondrial myopathy, AMD, heart failure) remain in earlier-phase development.

What is the mechanism of action for SS-31 elamipretide?

Cardiolipin binding in the inner mitochondrial membrane. The tetrapeptide accumulates electrostatically and hydrophobically, sequestering cardiolipin in the bent shape that supports cristae curvature, preventing peroxidation, and preserving electron transport chain function.

Key data point: Bhatt et al. (2020, Journal of the American College of Cardiology) reported that SS-31 (Elamipretide) administered for 4 weeks in heart failure with preserved ejection fraction (HFpEF) patients significantly improved 6-minute walk test distance — one of the few published human clinical datasets for a mitochondria-targeting peptide in a cardiovascular endpoint.

Summary

SS-31 elamipretide is the most clinically developed mitochondria-targeting peptide in current research, with a unique cardiolipin-binding mechanism that stabilises cristae architecture rather than scavenging radicals. The Phase 3 program covers Barth syndrome (FDA NDA submitted 2024 with Priority Review), primary mitochondrial myopathy, age-related macular degeneration, and heart failure with preserved ejection fraction. Effects on preserved mitochondrial function are documented across rodent and human tissue. Safety profile is favourable and the mechanism is mechanistically clean. If FDA-approved for Barth syndrome in 2026, elamipretide would be the first approved mitochondrial-targeted peptide therapeutic. Research-grade material is legal in Canada and the United States under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and aren’t intended for human consumption.